194 related articles for article (PubMed ID: 32933922)
1. Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli
Ciurea A; Micheroli R
Ann Rheum Dis; 2022 Nov; 81(11):e227. PubMed ID: 32933922
[No Abstract] [Full Text] [Related]
2. Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli
Huang JX; Leong PY; Wei JC
Ann Rheum Dis; 2022 Nov; 81(11):e226. PubMed ID: 32933918
[No Abstract] [Full Text] [Related]
3. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
[TBL] [Abstract][Full Text] [Related]
4. HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry.
Fröhlich F; Micheroli R; Hebeisen M; Kissling S; Bürki K; Exer P; Bräm R; Niedermann K; Möller B; Nissen MJ; Kyburz D; Andor M; Distler O; Scherer A; Ciurea A
Clin Rheumatol; 2023 May; 42(5):1267-1274. PubMed ID: 36574181
[TBL] [Abstract][Full Text] [Related]
5. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
Rheumatology (Oxford); 2021 Dec; 60(12):5743-5752. PubMed ID: 33725088
[TBL] [Abstract][Full Text] [Related]
6. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH;
Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491
[TBL] [Abstract][Full Text] [Related]
7. The Future of Axial Spondyloathritis Treatment.
Maguire S; Sengupta R; O'Shea F
Rheum Dis Clin North Am; 2020 May; 46(2):357-365. PubMed ID: 32340707
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review.
Eksin MA; Erden A; Güven SC; Armagan B; Ozdemir B; Karakas O; Omma A; Kucuksahin O
Immunotherapy; 2022 Apr; 14(6):401-408. PubMed ID: 35152720
[No Abstract] [Full Text] [Related]
9. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM; Deodhar A; Gensler LS; Dubreuil M; Yu D; Khan MA; Haroon N; Borenstein D; Wang R; Biehl A; Fang MA; Louie G; Majithia V; Ng B; Bigham R; Pianin M; Shah AA; Sullivan N; Turgunbaev M; Oristaglio J; Turner A; Maksymowych WP; Caplan L
Arthritis Rheumatol; 2019 Oct; 71(10):1599-1613. PubMed ID: 31436036
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
11. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis.
Armağan B; Kılıç L; Farisoğulları B; Yardımcı GK; Bilgin E; Bölek EÇ; Karadağ Ö; Bilgen ŞA; Kiraz S; Ertenli İ; Kalyoncu U
Rheumatol Int; 2023 Jan; 43(1):147-156. PubMed ID: 36129541
[TBL] [Abstract][Full Text] [Related]
12. Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis.
Huang JX; Lee YH; Leong PY; Wei JC
Int J Rheum Dis; 2024 Jan; 27(1):e15008. PubMed ID: 38140850
[No Abstract] [Full Text] [Related]
13. Treatment of axial spondyloarthritis: an update.
Danve A; Deodhar A
Nat Rev Rheumatol; 2022 Apr; 18(4):205-216. PubMed ID: 35273385
[TBL] [Abstract][Full Text] [Related]
14. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Gladman.
Landewé RB; Braun J
Ann Rheum Dis; 2023 Aug; 82(8):e188. PubMed ID: 35487678
[No Abstract] [Full Text] [Related]
15. Treatment of non-radiographic axial spondyloarthritis: it is only the beginning.
van der Horst-Bruinsma IE
Ann Rheum Dis; 2013 Jun; 72(6):789-90. PubMed ID: 23667168
[No Abstract] [Full Text] [Related]
16. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Lavie F; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar AA; Østergaard M; Baraliakos X
Ann Rheum Dis; 2023 Aug; 82(8):e187. PubMed ID: 35487679
[No Abstract] [Full Text] [Related]
17. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
Siebert S; Marzo-Ortega H
Ann Rheum Dis; 2023 Aug; 82(8):e185. PubMed ID: 34844925
[No Abstract] [Full Text] [Related]
18. Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun
Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RB; van der Heijde D
Ann Rheum Dis; 2023 Sep; 82(9):e206. PubMed ID: 36878690
[No Abstract] [Full Text] [Related]
19. Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis.
Gentileschi S; Rigante D; Sota J; Lopalco G; Giannotta MG; Emmi G; Di Scala G; Iannone F; Fabiani C; Frediani B; Cantarini L
Mediators Inflamm; 2020; 2020():6983272. PubMed ID: 32317863
[TBL] [Abstract][Full Text] [Related]
20. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physicianreported spondylitis'?' by Siebert and Marzo-Ortega.
Braun J; Landewé RB
Ann Rheum Dis; 2023 Aug; 82(8):e186. PubMed ID: 34844931
[No Abstract] [Full Text] [Related]
[Next] [New Search]
